Atrial fibrillation in breast cancer therapy: does tamoxifen confer a lower risk than aromatase inhibitors?
Abstract Introduction Aromatase inhibitors (AIs) have been linked to increased atrial fibrillation(AF) risk due to estrogen depletion however tamoxifen's effect on AF remains conflicting. This study investigates the risk of AF associated with AI use compared to tamoxifen in breast cancer patien...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Cardio-Oncology |
| Online Access: | https://doi.org/10.1186/s40959-025-00352-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849704018700402688 |
|---|---|
| author | Patrick A. Kwaah Samuel A. Mensah Emmanuel A. Agyemang Joseph S. Kekrebesi Daniil Katkov Abraham Carboo Grace Appah Hamza A. Rashid Jennifer M. Kwan |
| author_facet | Patrick A. Kwaah Samuel A. Mensah Emmanuel A. Agyemang Joseph S. Kekrebesi Daniil Katkov Abraham Carboo Grace Appah Hamza A. Rashid Jennifer M. Kwan |
| author_sort | Patrick A. Kwaah |
| collection | DOAJ |
| description | Abstract Introduction Aromatase inhibitors (AIs) have been linked to increased atrial fibrillation(AF) risk due to estrogen depletion however tamoxifen's effect on AF remains conflicting. This study investigates the risk of AF associated with AI use compared to tamoxifen in breast cancer patients. Methods A retrospective cohort analysis was conducted using the TriNetX database from 2015 to 2024. Breast cancer patients were categorized into two groups: AI users (anastrozole, exemestane, or letrozole) and tamoxifen users. A propensity score matching (1:1) adjusted for demographics, comorbidities, concurrent therapies, and lab values. The incidence of AF was assessed at 1, 5, and 10-years post-treatment initiation. Results The study included 220,552 AI users and 73,388 tamoxifen users before matching, with 54,175 patients in each group after matching. At 1 year, AI users had a higher risk of AF (0.5% vs. 0.4%, RR: 1.36, p = 0.001). At 5 years, AF incidence remained higher in the AI group (1.2% vs. 1.1%, RR: 1.13, p = 0.035).However at 10 years, the difference in AF risk between the two groups was no longer significant (1.6% vs. 1.5%, RR: 1.05, p = 0.295). Conclusion AI use is associated with a higher risk of AF than tamoxifen in the first 5 years of treatment, but the risk equalizes at 10 years. Long-term hormonal therapy has an increased risk of AF, highlighting the need for ongoing monitoring and management of risk factors. |
| format | Article |
| id | doaj-art-ff27893ea37c4833b883d917928eef3d |
| institution | DOAJ |
| issn | 2057-3804 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardio-Oncology |
| spelling | doaj-art-ff27893ea37c4833b883d917928eef3d2025-08-20T03:16:56ZengBMCCardio-Oncology2057-38042025-05-011111610.1186/s40959-025-00352-3Atrial fibrillation in breast cancer therapy: does tamoxifen confer a lower risk than aromatase inhibitors?Patrick A. Kwaah0Samuel A. Mensah1Emmanuel A. Agyemang2Joseph S. Kekrebesi3Daniil Katkov4Abraham Carboo5Grace Appah6Hamza A. Rashid7Jennifer M. Kwan8Department of Internal Medicine, Yale School of MedicineDepartment of Internal Medicine, West Virginia UniversityDepartment of Internal Medicine, Newark Beth Israel Medical CenterDivision of Cardiology, Emory University School of MedicineDepartment of Internal Medicine, Yale School of MedicineDepartment of Internal Medicine, Yale School of MedicineDepartment of Internal Medicine, Yale School of MedicineDepartment of Internal Medicine, Yale School of MedicineSection of Cardiovascular Medicine, Yale School of MedicineAbstract Introduction Aromatase inhibitors (AIs) have been linked to increased atrial fibrillation(AF) risk due to estrogen depletion however tamoxifen's effect on AF remains conflicting. This study investigates the risk of AF associated with AI use compared to tamoxifen in breast cancer patients. Methods A retrospective cohort analysis was conducted using the TriNetX database from 2015 to 2024. Breast cancer patients were categorized into two groups: AI users (anastrozole, exemestane, or letrozole) and tamoxifen users. A propensity score matching (1:1) adjusted for demographics, comorbidities, concurrent therapies, and lab values. The incidence of AF was assessed at 1, 5, and 10-years post-treatment initiation. Results The study included 220,552 AI users and 73,388 tamoxifen users before matching, with 54,175 patients in each group after matching. At 1 year, AI users had a higher risk of AF (0.5% vs. 0.4%, RR: 1.36, p = 0.001). At 5 years, AF incidence remained higher in the AI group (1.2% vs. 1.1%, RR: 1.13, p = 0.035).However at 10 years, the difference in AF risk between the two groups was no longer significant (1.6% vs. 1.5%, RR: 1.05, p = 0.295). Conclusion AI use is associated with a higher risk of AF than tamoxifen in the first 5 years of treatment, but the risk equalizes at 10 years. Long-term hormonal therapy has an increased risk of AF, highlighting the need for ongoing monitoring and management of risk factors.https://doi.org/10.1186/s40959-025-00352-3 |
| spellingShingle | Patrick A. Kwaah Samuel A. Mensah Emmanuel A. Agyemang Joseph S. Kekrebesi Daniil Katkov Abraham Carboo Grace Appah Hamza A. Rashid Jennifer M. Kwan Atrial fibrillation in breast cancer therapy: does tamoxifen confer a lower risk than aromatase inhibitors? Cardio-Oncology |
| title | Atrial fibrillation in breast cancer therapy: does tamoxifen confer a lower risk than aromatase inhibitors? |
| title_full | Atrial fibrillation in breast cancer therapy: does tamoxifen confer a lower risk than aromatase inhibitors? |
| title_fullStr | Atrial fibrillation in breast cancer therapy: does tamoxifen confer a lower risk than aromatase inhibitors? |
| title_full_unstemmed | Atrial fibrillation in breast cancer therapy: does tamoxifen confer a lower risk than aromatase inhibitors? |
| title_short | Atrial fibrillation in breast cancer therapy: does tamoxifen confer a lower risk than aromatase inhibitors? |
| title_sort | atrial fibrillation in breast cancer therapy does tamoxifen confer a lower risk than aromatase inhibitors |
| url | https://doi.org/10.1186/s40959-025-00352-3 |
| work_keys_str_mv | AT patrickakwaah atrialfibrillationinbreastcancertherapydoestamoxifenconferalowerriskthanaromataseinhibitors AT samuelamensah atrialfibrillationinbreastcancertherapydoestamoxifenconferalowerriskthanaromataseinhibitors AT emmanuelaagyemang atrialfibrillationinbreastcancertherapydoestamoxifenconferalowerriskthanaromataseinhibitors AT josephskekrebesi atrialfibrillationinbreastcancertherapydoestamoxifenconferalowerriskthanaromataseinhibitors AT daniilkatkov atrialfibrillationinbreastcancertherapydoestamoxifenconferalowerriskthanaromataseinhibitors AT abrahamcarboo atrialfibrillationinbreastcancertherapydoestamoxifenconferalowerriskthanaromataseinhibitors AT graceappah atrialfibrillationinbreastcancertherapydoestamoxifenconferalowerriskthanaromataseinhibitors AT hamzaarashid atrialfibrillationinbreastcancertherapydoestamoxifenconferalowerriskthanaromataseinhibitors AT jennifermkwan atrialfibrillationinbreastcancertherapydoestamoxifenconferalowerriskthanaromataseinhibitors |